AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Nuwellis to present at Webull Financial Corporate Connect webinar series.
ByAinvest
Friday, Aug 15, 2025 8:31 am ET1min read
Nuwellis, Inc. (Nasdaq: NUWE) will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech from August 19-21, 2025. John Erb, President and CEO, will present on August 21 at 2:40 PM ET. The webinar series is hosted by Webull Financial, a leading online brokerage platform that aims to empower self-directed investors with innovative tools and cutting-edge technology.
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company specializing in fluid management solutions for critically ill patients, has announced its participation in the upcoming Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. The virtual event will be held from August 19 to 21, 2025, with Nuwellis' President and Chief Executive Officer, John Erb, scheduled to present on August 21 at 2:40 PM ET.The Webull Financial Corporate Connect Webinar Series is designed to bring together industry leaders and innovators to discuss advancements and trends in the biotech and medtech sectors. This year's event will feature a range of presentations from leading companies, offering insights into the latest developments and technologies in these fields.
Webull Financial, the host of the webinar series, is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull aims to revolutionize the way individuals approach investing. The platform is registered with the Securities and Exchange Commission (SEC) and the Commodity Futures Trading Commission (CFTC) and is a member of various industry regulatory bodies, including the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC).
Nuwellis, Inc. is dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. This system is designed to manage fluid overload in critically ill patients, offering a more efficient and effective treatment option. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland.
For further information about Nuwellis, Inc. or to register for the webinar, please visit [Nuwellis' website](https://www.nuwellis.com) or contact the company's investor relations team at [Jenene Thomas](mailto:nuwe@jtcir.com) or the media contact [Leah McMullen](mailto:Leah.mcmullen@nuwellis.com).
References:
[1] https://www.marketscreener.com/news/nuwellis-inc-to-present-at-the-webull-financial-corporate-connect-webinar-series-biotech-medtech-ce7c51dedc81f726
[2] https://www.stocktitan.net/news/NUWE/nuwellis-inc-to-present-at-the-webull-financial-corporate-connect-5e9f6h5wdukn.html
[3] https://www.globenewswire.com/news-release/2025/08/15/3134202/26106/en/Nuwellis-Inc-to-Present-at-the-Webull-Financial-Corporate-Connect-Webinar-Series-Biotech-MedTech.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet